Related Experiment Video

Updated: Jan 10, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

505

Effect of carperitide on clinical outcomes among patients with acute heart failure: a meta-analysis of randomized and

Tsuyoshi Shiga1, Atsushi Suzuki2, Sachie Inoue3,4

  • 1Department of Clinical Pharmacology and Therapeutics, The Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo, 105-8461, Japan. shiga@jikei.ac.jp.

BMC Cardiovascular Disorders
|November 28, 2025
PubMed

Insights

This meta-analysis found that carperitide treatment for acute heart failure (AHF) did not significantly reduce in-hospital mortality in randomized controlled trials (RCTs). Overall, carperitide showed no superiority over non-carperitide treatments for AHF outcomes.

Area of Science:

  • Cardiology
  • Clinical Pharmacology

Background:

  • Carperitide, an α-human A-type natriuretic peptide, is used for acute heart failure (AHF) treatment, primarily in Japan.
  • Its clinical effectiveness in AHF patients remains to be established.
  • This meta-analysis aimed to evaluate carperitide's impact on AHF clinical outcomes.

Purpose of the Study:

  • To assess the clinical effectiveness of carperitide in patients with acute heart failure (AHF).
  • To evaluate the effect of carperitide on in-hospital mortality and other clinical outcomes in AHF patients.

Main Methods:

  • Searched MEDLINE, ICHUSHI, Cochrane Library, and Web of Science for randomized controlled trials (RCTs) and propensity score matching (PSM) studies.
  • Primary outcome: in-hospital mortality. Secondary outcomes: long-term mortality, HF rehospitalization, length of hospital stay, and hypotension.
  • Calculated pooled odds ratios (ORs)/mean differences and 95% confidence intervals (CIs) using a random effects model.

Main Results:

  • Nine studies (4 RCTs, 5 PSM) were included.
  • Combined RCTs and PSM studies showed higher in-hospital mortality with carperitide (OR 1.38; 95% CI 1.07-1.78).
  • RCTs alone found no significant difference in in-hospital mortality (OR 0.85; 95% CI: 0.07-10.49); no differences in other outcomes.

Conclusions:

  • Carperitide therapy may not be superior to non-carperitide therapy for reducing in-hospital mortality in AHF.
  • Carperitide did not demonstrate improved long-term outcomes compared to non-carperitide treatments.
  • Further research may be needed to clarify carperitide's role in AHF management.
Abstract

Keywords:
Acute heart failureAtrial natriuretic peptideCarperitideMeta-analysisMortality

More Related Videos

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.8K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.9K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
888
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
314
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
200
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
737
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
768
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
235